Molecular genetics and targeted therapeutics in biliary tract carcinoma

Table 4 Ongoing clinical trials of targeted therapeutics in cholangiocarcinoma or gallbladder adenocarcinoma

Treatment	Phase	Date of completion	Sponsoring institutions	ClinicalTrials.gov identifier
GEMOX + Erlotinib	II	Dec., 2014	New Mexico Cancer Care Alliance	NCT00832637
Sorafenib + Erlotinib	II	May, 2014	National Cancer Institute	NCT01093222
GEMOX vs GEMOX + Cetuximab	II	Dec., 2014	National Health Research Institutes, Taiwan	NCT01267344
GEMOX + Panitumumab vs GEMOX + Bevacizumab	II	Aug., 2015	Vejle Hospital	NCT01206049
Cisplatin + Gemcitabine + Panitumumab vs Cisplatin + Gemcitabine	II	June, 2014	Hannover Medical School	NCT01320254
GEMOX + Panitumumab vs GEMOX alone	II	March, 2015	Fondazione del Piemonte per l'Oncologia	NCT01389414
Gemcitabine + Capecitabine + Bevacizumab	II	May, 2014	Roswell Park Cancer Institute	NCT01007552
Everolimus	II	June, 2014	Ratchavithi Hospital	NCT01525719
GEMOX + Sorafenib	I/II	Aug., 2014	University of Miami Sylvester Comprehensive Cancer Center	NCT00955721
Gemcitabine + Cisplatin + Sorafenib	II	March, 2014	Memorial Sloan-Kettering Cancer Center	NCT00919061
Gemcitabine + Cisplatin + Selumetinib	I/II	Jan., 2015	AstraZeneca	NCT01242605
Gemcitabine + Cisplatin + Selumetinib	I	Dec., 2014	AstraZeneca	NCT01949870
Trametinib	II	Feb., 2015	GlaxoSmithKline	NCT01943864
Trametinib vs 5-FU + Leucovorin vs Capecitabine	II	July, 2016	National Cancer Institute	NCT02042443
Celecoxib	IV	Dec., 2015	Seoul National University Hospital	NCT01111591
Regorafenib	II	Feb., 2018	University of Pittsburgh	NCT02053376
Regorafenib	II	Oct., 2018	H. Lee Moffitt Cancer Center and Research Institute	NCT02115542
Regorafenib + mGEMOX	I/II	April, 2019	Institut du Cancer de Montpellier-Val d'Aurelle	NCT02386397

5-FU: 5-fluorouracil; GEMOX: Gemcitabine and oxaliplatin.